HCA vs REGN
HCA: One of the largest U.S. for-profit hospital operators, managing 190 hospitals and 121 ambulatory surgery centers across 19 states and England, generating $76+ billion in annual revenue. REGN: Regeneron develops and commercializes monoclonal antibody and other biologics therapies across immunology, oncology, infectious disease, and other therapeutic areas.
Side-by-side fundamentals
| Metric | HCA | REGN | Edge |
|---|---|---|---|
| Price as of 2026-07-09 close | $409.01 | $667.95 | |
| Market cap as of 2026-07-10 | $89.9B | $69.9B | |
| P/E as of 2026-07-10 | 13.23 | 15.80 | HCA lower |
| PEG as of 2026-07-10 | 1.31 | 1.01 | REGN lower |
| Net margin as of 2026-07-10 | +8.9% | +29.6% | REGN higher |
| Gross margin as of 2026-07-10 | +85.0% | +85.7% | REGN higher |
| Operating margin as of 2026-07-10 | +15.7% | +24.3% | REGN higher |
| ROE as of 2026-07-10 | +695.7% | +14.3% | HCA higher |
| ROA as of 2026-07-10 | +11.3% | +11.1% | HCA higher |
| Debt / equity as of 2026-07-10 | 125.80 | 0.09 | REGN lower |
| Revenue growth (YoY) as of 2026-07-10 | +6.7% | +5.9% | HCA higher |
| Revenue CAGR (3y) SEC XBRL | +7.9% | +5.6% | HCA higher |
| Dividend yield as of 2026-07-10 | +0.8% | +0.6% | HCA higher |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-10 | 1.11 | 0.21 | |
| 1-year return as of 2026-07-09 close | +8.7% | +20.9% | REGN higher |
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.